Patents by Inventor Silvia PAVAN
Silvia PAVAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240082410Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of membrane type 1 metalloprotease (MT1-MMP). The invention also describes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups which have utility in imaging and targeted cancer therapy.Type: ApplicationFiled: May 11, 2023Publication date: March 14, 2024Inventors: Daniel Paul TEUFEL, Catherine Lucy STACE, Silvia PAVAN, Edward WALKER, Leonardo BALDASSARRE
-
Publication number: 20240000957Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).Type: ApplicationFiled: May 8, 2023Publication date: January 4, 2024Inventors: Liuhong CHEN, Philip HUXLEY, Silvia PAVAN, Katerine VAN RIETSCHOTEN
-
Patent number: 11833211Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).Type: GrantFiled: September 23, 2022Date of Patent: December 5, 2023Assignee: BicycleTx LimitedInventors: Liuhong Chen, Philip Huxley, Silvia Pavan, Katerine Van Rietschoten
-
Patent number: 11814447Abstract: A peptide ligand specific for EphA2 comprising a polypeptide comprising three residues selected from cysteine, L-2,3-diaminopropionic acid (Dap), N-beta-alkyl-L-2,3-diaminopropionic acid (N-AlkDap) and N-beta-haloalkyl-L-2,3-diaminopropionic acid (N-HAlkDap), with the proviso that at least one of said three residues is selected from Dap, N-AlkDap or N-HAlkDap, the said three residues being separated by at least two loop sequences, and a molecular scaffold, the peptide being linked to the scaffold by covalent alkylamino linkages with the Dap or N-AlkDap or N-HAlkDap residues of the polypeptide and by thioether linkages with the cysteine residues of the polypeptide when the said three residues include cysteine, such that two polypeptide loops are formed on the molecular scaffold.Type: GrantFiled: June 18, 2019Date of Patent: November 14, 2023Assignee: BicycleRD LimitedInventors: Daniel Paul Teufel, Gemma Mudd, Silvia Pavan
-
Publication number: 20230340020Abstract: A peptide ligand specific for MT1-MMP comprising a polypeptide comprising two diaminopropionic acid (Dap) or N-alkyldiaminopropionic acid (N-AlkDap) residues, and a third residue selected from cysteine, Dap or N-AlkDap, separated by at least two loop sequences, and a molecular scaffold, the peptide being linked to the scaffold by covalent alkylamino linkages with the Dap or N-AlkDap residues of the polypeptide and by covalent thioether linkages with the cysteine when the third residue is cysteine, such that two polypeptide loops are formed on the molecular scaffold, wherein the peptide ligand comprises an amino acid sequence of formula (II): -A1-X1-U/O2-X3-X4-G5-A2-E6-D7-F8-Y9-X10-X11-A3- (SEQ ID NO: 1) (II) or a pharmaceutically acceptable salt thereof; wherein: A1, A2, and A3 are independently cysteine, L-2,3-diaminopropionic acid (Dap), N-beta-alkyl-L-2,3-diaminopropionic acid (N-AlkDap), or N-beta-haloalkyl-L-2,3-diaminopropionic acid (N-HAlkDap), provided that at least one of A1, A2, and A3 is Dap, N-AlkType: ApplicationFiled: September 16, 2022Publication date: October 26, 2023Inventors: Daniel TEUFEL, Gemma MUDD, Silvia PAVAN
-
Patent number: 11730819Abstract: A compound comprising at least one looped peptide structure attached via at least one alkylamino linkage to a scaffold. Preferably the looped peptide structure is a Bicycle structure comprising two peptide loops attached to the scaffold via two alkylamino linkages and one thioether linkage, one of the linkages being common to both loops.Type: GrantFiled: December 20, 2017Date of Patent: August 22, 2023Assignee: BicycleTx LimitedInventors: Daniel Teufel, Gemma Mudd, Silvia Pavan
-
Patent number: 11696956Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).Type: GrantFiled: December 19, 2018Date of Patent: July 11, 2023Assignee: BicycleTx LimitedInventors: Liuhong Chen, Philip Huxley, Silvia Pavan, Katerine Van Rietschoten
-
Patent number: 11672868Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of membrane type 1 metalloprotease (MT1-MMP). The invention also describes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups which have utility in imaging and targeted cancer therapy.Type: GrantFiled: July 22, 2021Date of Patent: June 13, 2023Assignee: BicycleRD LimitedInventors: Daniel Paul Teufel, Catherine Lucy Stace, Silvia Pavan, Edward Walker, Leonardo Baldassarre
-
Publication number: 20230144799Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).Type: ApplicationFiled: September 23, 2022Publication date: May 11, 2023Inventors: Liuhong CHEN, Philip HUXLEY, Silvia Pavan, Katerine Van Rietschoten
-
Patent number: 11623012Abstract: The present invention relates to polypeptides which are covalently bound to aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and dmg conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).Type: GrantFiled: December 19, 2018Date of Patent: April 11, 2023Assignee: BicycleRD LimitedInventors: Liuhong Chen, Silvia Pavan, Catherine Stace, Daniel Teufel, Katerine Van Rietschoten
-
Patent number: 11484602Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).Type: GrantFiled: December 14, 2018Date of Patent: November 1, 2022Assignee: BicycleTx LimitedInventors: Liuhong Chen, Philip Huxley, Silvia Pavan, Katerine Van Rietschoten
-
Publication number: 20220289792Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).Type: ApplicationFiled: December 19, 2018Publication date: September 15, 2022Inventors: Liuhong CHEN, Philip HUXLEY, Silvia PAVAN, Katerine VAN RIETSCHOTEN
-
Publication number: 20220194983Abstract: A peptide ligand specific for prostate specific membrane antigen (PSMA) comprising a polypeptide comprising three residues selected from cysteine, L-2,3-diaminopropionic acid (Dap), N-beta-alkyl-L-2,3-diaminopropionic acid (N-AlkDap) and N-beta-haloalkyl-L-2,3-diaminopropionic acid (N-HAlkDap), with the proviso that at least one of said three residues is selected from Dap, N-AlkDap or N-HAlkDap, the said three residues being separated by at least two loop sequences, and a molecular scaffold, the peptide being linked to the scaffold by covalent alkylamino linkages with the Dap or N-AlkDap or N-HAlkDap residues of the polypeptide and by thioether linkages with the cysteine residues of the polypeptide when the said three residues include cysteine, such that two polypeptide loops are formed on the molecular scaffold.Type: ApplicationFiled: June 19, 2019Publication date: June 23, 2022Inventors: Daniel TEUFEL, Gemma MUDD, Silvia PAVAN, Kevin MCDONNELL, Punit UPADHYAYA
-
Publication number: 20220133733Abstract: The present invention relates to polypeptides which are covalently bound to aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of CD38. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD38.Type: ApplicationFiled: January 15, 2020Publication date: May 5, 2022Inventors: Leonardo BALDASSARRE, Rachid LANI, Silvia PAVAN, Catherine STACE, Daniel TEUFEL
-
Publication number: 20220064218Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of CD38.The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and dmg conjugates in preventing, suppressing or treating a disease or disorder mediated by CD38.Type: ApplicationFiled: January 15, 2020Publication date: March 3, 2022Inventors: Leonardo BALDASSARRE, Rachid LANI, Silvia PAVAN, Catherine STACE, Daniel TEUFEL
-
Patent number: 11241473Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.Type: GrantFiled: September 2, 2020Date of Patent: February 8, 2022Assignee: BicycleTx LimitedInventors: Paul John Beswick, Gabriela Ivanova-Berndt, Gemma Elizabeth Mudd, Silvia Pavan, Michael Skynner, Daniel Paul Teufel, Katerine Van Rietschoten
-
Publication number: 20220023432Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of membrane type 1 metalloprotease (MT1-MMP). The invention also describes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups which have utility in imaging and targeted cancer therapy.Type: ApplicationFiled: July 22, 2021Publication date: January 27, 2022Inventors: Daniel Paul TEUFEL, Catherine Lucy Stace, Silvia Pavan, Edward Walker, Leonardo Baldassarre
-
Patent number: 11103591Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of membrane type 1 metalloprotease (MT1-MMP). The invention also describes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups which have utility in imaging and targeted cancer therapy.Type: GrantFiled: December 6, 2019Date of Patent: August 31, 2021Assignee: BicycleRD LimitedInventors: Daniel Paul Teufel, Catherine Lucy Stace, Silvia Pavan, Edward Walker, Leonardo Baldassarre
-
Publication number: 20210261620Abstract: A peptide ligand specific for EphA2 comprising a polypeptide comprising three residues selected from cysteine, L-2,3-diaminopropionic acid (Dap), N-beta-alkyl-L-2,3-diaminopropionic acid (N-AlkDap) and N-beta-haloalkyl-L-2,3-diaminopropionic acid (N-HAlkDap), with the proviso that at least one of said three residues is selected from Dap, N-AlkDap or N-HAlkDap, the said three residues being separated by at least two loop sequences, and a molecular scaffold, the peptide being linked to the scaffold by covalent alkylamino linkages with the Dap or N-AlkDap or N-HAlkDap residues of the polypeptide and by thioether linkages with the cysteine residues of the polypeptide when the said three residues include cysteine, such that two polypeptide loops are formed on the molecular scaffold.Type: ApplicationFiled: June 18, 2019Publication date: August 26, 2021Inventors: Daniel TEUFEL, Gemma MUDD, Silvia PAVAN
-
Publication number: 20210147485Abstract: A peptide ligand specific for integrin ?v?3 comprising a polypeptide comprising three residues selected from cysteine, L-2,3-diaminopropionic acid (Dap), N-beta-alkyl-L-2,3-diaminopropionic acid (N-AlkDap) and N-beta-haloalkyl-L-2,3-diaminopropionic acid (N-HAlkDap), with the proviso that at least one of said three residues is selected from Dap, N-AlkDap or N-HAlkDap, the said three residues being separated by at least two loop sequences, and a molecular scaffold, the peptide being linked to the scaffold by covalent alkylamino linkages with the Dap or N-AlkDap or N-HAlkDap residues of the polypeptide and by thioether linkages with the cysteine residues of the polypeptide when the said three residues include cysteine, such that two polypeptide loops a formed on the molecular scaffold. Also provided are drug conjugates comprising the peptide ligands conjugated to one or more effector groups and pharmaceutical compositions comprising the conjugates.Type: ApplicationFiled: June 18, 2019Publication date: May 20, 2021Inventors: Daniel TEUFEL, Gemma MUDD, Silvia PAVAN